Previous 10 | Next 10 |
home / stock / bthcf / bthcf news
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (“ Algernon ” or “ Company ”) ( CSE: AGN ) ( FRANKFURT: AGW ) ( OTCB...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (“ Algernon ” or “ Company ”) ( CSE: AGN ) ( FRANKFURT: AGW ) ( OT...
Algernon Pharmaceuticals ( OTCQB:BTHCF ) reports that its lead drug for inflammatory bowel disease (IBD) is Emoxypine (NP-178), an orally delivered small molecule. More news on: Algernon Pharmaceuticals Inc., Healthcare stocks news, Read more ...
VANCOUVER, British Columbia, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”), a clinical stage pharmaceutical development company, is pleased to report that its lead ...
VANCOUVER, British Columbia, July 31, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”), a clinical stage pharmaceutical development company, is pleased to report that its lead ...
VANCOUVER, British Columbia, July 29, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”), a clinical stage pharmaceutical development company, is pleased to announce that NP-120,...
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, July 04, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) ...
VANCOUVER, British Columbia, July 03, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”), a clinical stage pharmaceutical development company, is pleased to announce that NP-120,...
VANCOUVER, British Columbia, April 04, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company is pleased to announce that Dr. Walt...
VANCOUVER, British Columbia, April 01, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company is pleased to announce that after ad...
News, Short Squeeze, Breakout and More Instantly...
Breathtec Biomedical Inc Company Name:
BTHCF Stock Symbol:
OTCMKTS Market:
VANCOUVER, British Columbia, May 12, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company announces that NP-120 (Ifenpro...
VANCOUVER, British Columbia, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”), a clinical stage pharmaceutical development company, is pleased to announce that Dr. Mar...
VANCOUVER, British Columbia, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”), a clinical stage pharmaceutical development company, is pleased to announce that it will...